This is a proof (draft) Hansard, not the final version.

The Parliament has not yet published the final text for this day, so the wording, who said what and the results of divisions may change.

Senate debates Bills

Therapeutic Goods Amendment (Medicines Shortages and Other Measures) Bill 2026, Therapeutic Goods (Charges) Amendment Bill 2026; Second Reading


Anne Ruston

Anne Ruston SA, Liberal Party, Shadow Minister for Health and Aged Care

7:22 pm

I rise to speak on the Therapeutic Goods Amendment (Medicines Shortages and Other Measures) Bill 2026 and the related Therapeutic Goods (Charges) Amendment Bill 2026. Let me say at the outset the coalition will not be opposing these bills, but I want to be very clear about what these bills do and what they don't do. The Therapeutic Goods Amendment (Medicines Shortages and Other Measures) Bill 2026 is about knowing sooner that a medicine is about to run out. It is not a bill about making sure that that medicine doesn't run out.

Under this bill, a company that decides to stop supplying a reportable medicine in Australia must tell the regulator at least 12 months ahead or as soon as it practically can. If that plan changes, it must say so. The secretary will be able to ask the supplier of any approved medicine—not just a reportable one—whether it's available, running short or on its way out altogether. The Medicines Watch List, the list of medicines whose loss would hurt patients most, will be kept current as the documents it relies on change.

The bill also lets near-identical biological medicines from the same company share one entry on the register, rather than a new listing for every pack size. The charges bill sets the fees for those groups. There will be less duplication and less red tape, and that's sensible. It puts beyond doubt the power of authorised officers to enter and inspect clinical trial sites so the people who volunteer for those trials can trust that they're being given in a safe environment. None of that is controversial.

Since this bill passed the other place in August, the Community Affairs Legislation Committee has examined it and reported. The nurses and midwives called it a positive first step and said more work was needed. The physicians told the committee that the bill on its own is unlikely to deliver a comprehensive solution. They support the bill and so do we, but none of them believes it solves the problem, because there is a problem.

Australia import about 90 per cent of the medicines that we rely on, and we account for barely two per cent of the global market. When a factory overseas stumbles or a shipping route closes, we are a long way down the queue. We saw that again this year. When conflict broke out in the Middle East in March, medicines bound for Australia had to be rerouted. Throughout 2025, more than 400 medicines were listed as in shortage on any given day. That has not improved. Just weeks ago, the number was around 420. Forty of them were considered critical.

And they keep coming back. An analysis of the TGA's own data published just last week found that more than half of those critical shortages had happened before and thirteen of those medicines had been critically short more than once. Take Bicillin, a long-acting penicillin used to treat syphilis and to protect people living with rheumatic heart disease. It has been in short supply since April last year, our emergency supplies ran out in September and relief is not expected until next March. For Aboriginal and Torres Strait Islander communities, where rheumatic heart disease is still far too common, that is not an inconvenience; it is plainly dangerous.

Think about what that means at the pharmacy counter. It means an older Australian who has taken the same tablet for years being told it simply isn't available, and far too often the GP is the last to find out. When nearly 1,500 GPs were polled earlier last year, almost three in four said they usually first heard about a shortage from their patients. The patients told the doctor. That is a backwards way of going about it. So, yes, earlier warning certainly helps, but a warning is not a solution. You cannot fill a prescription with a notice.

We know prevention can work because we've seen it. It was the coalition that made medicine shortages reporting mandatory from January 2019 and it was the coalition that legislated the minimum stockholding requirements so companies must hold months of stock of key PBS medicines here in Australia. Earlier this year, the department's own review found those requirements had reduced both the number and the severity of shortages.

That is what it looks like when you stop a shortage before it starts. Contrast that with the government's handling of IV fluids—the saline drips that every operating theatre and emergency department depends on. By the government's own admission, it knew a shortage was coming from the middle of May 2023. By the middle of 2024, hospitals were told that they had to ration. At the time, I asked a simple question: what does a future made in Australia actually mean if the government can't even guarantee a supply of saline solution? The answer came in March 2025—a $20 million investment matched by industry to expand local production—and we welcomed it. We welcomed the fact that the acute shortage was to be resolved. The minister told Australians we would no longer be hostage to overseas supply, but the full extra capacity is not due until 2027. That's around four years from the first warning that a fix was needed.

That brings me to our two amendments. The coalition will move two amendments. The first is the second reading amendment circulated in my name. When it was moved in the other place, the government voted it down. We will move it again here because the problem has not gone away. It asks the Senate to recognise how dependent we are on imports, how stubborn the number of shortages has been and that substitution approvals have more than doubled since 2018. It notes that this bill does not deal with the underlying cause. It calls on the government to do what it has so far avoided doing—to develop a comprehensive medicine shortage policy to build our sovereign capability so more essential medicines are made here at home in Australia and to set targets to bring the number of shortages down.

The second amendment, which I'll move in the committee stage, puts that work into law. It requires the minister to commission regular independent reviews of Australia's medicines security. The first must begin within six months of this law taking effect and be finished within a year—and, after that, there must be a fresh review at least every five years. When the same medicines run short again and again, that is not bad luck; it is a pattern. A pattern can be found and a pattern can be fixed. Each review must look at the questions that these bills leave unanswered—how much we rely on medicines and ingredients made overseas, which critical medicines have no safe substitute, whether we are holding enough stock and whether we could make more of it here, and what shortages mean for hospitals, for aged care, for general practice, for Aboriginal community controlled health services and for patients in rural, regional and remote Australia. It must hear from people who live with this every day—doctors, nurses, pharmacists, patients, wholesalers, manufacturers and state and territory governments. The report must be tabled in this parliament, and the government must table its response to every recommendation within six months. It will not stop every shortage—nothing can—but it means the hard questions get asked and answered out in the open before the next crisis rather than after it. If no-one measures it, no-one is accountable for it.

The coalition will not stand in the way of these bills. They will help Australians see the next shortage coming. But our job in this place is to make sure it never arrives at all. An early warning is welcome, but a warning is not a solution. I commend our amendments to the Senate and I urge the government and the crossbench to support them, because patients and the people who care for them deserve nothing less.

Charlotte Walker

Charlotte Walker SA, Australian Labor Party

7:31 pm

Most Australians probably don't spend much time thinking about medicines supply chains—and why should they? By all economic norms of globalisation, these aren't concerns that should live rent free in our minds. But, as we've seen in the past 12 months, when global supply chains get disrupted the knock-on effects spread to far-reaching places. For most Aussies, when they go to the pharmacy with a prescription they should expect it to be filled. They expect that the medicine their doctor has prescribed will be available and affordable, and that they will get it on the day. These are normal and reasonable expectations in a developed country like Australia.

But we know that, for a growing number of Australians, this isn't the reality anymore. We've seen shortages of ADHD medication, hormone replacement therapies, contraceptive pills, diabetes medication and even IV fluids. These are medications used by thousands of Australians every day that they rely on to manage chronic conditions, to maintain their health and, in many cases, to stay alive. When these medications suddenly become unavailable, the consequences can be devastating. For someone managing ADHD, it can mean weeks of struggling to concentrate at work or university. For a woman going through menopause, it might mean being unable to access hormone replacement therapy that has finally made her symptoms manageable. For someone with a serious chronic illness, it could mean having to change treatment that has taken years to get right. For healthcare workers, it means spending valuable time trying to find alternatives, contacting suppliers, rewriting prescriptions and reassuring understandably frustrated patients. None of this is good enough, and that's why the Albanese Labor government is taking further action to strengthen Australia's medicines supply chain.

The Therapeutic Goods (Charges) Amendment Bill 2026 and the Therapeutic Goods Amendment (Medicines Shortages and Other Measures) Bill 2026 are about making our medicines system more responsive, more transparent and better equipped to deal with shortages before they become full-blown crises. While Australia can't control every disruption to global medicines supply chains, we can absolutely improve how we prepare for them and respond when things go wrong. We as a country are particularly vulnerable to these kinds of disruptions. We're a relatively small market, geographically isolated and heavily dependent on medicines manufactured overseas. A manufacturing problem on the other side of the world, a shipping disruption or an unexpected surge in demand can quickly become a problem for Australian patients. These problems aren't always predictable, but we can make sure that, when a pharmaceutical company knows that a medicine is going to become unavailable, the people responsible for managing that shortage find out as early as possible. This is one of the central purposes of this legislation. Currently, pharmaceutical sponsors are required to notify the TGA when they decide to permanently discontinue a medicine, but the supporting requirements differ depending on whether discontinuation is considered critical. For critical medications, 12 months notice is needed, but for other medication only six months is deemed necessary. This bill simplifies this system and means that sponsors will be required to give 12 months notice of planned discontinuation for all reportable medicines. This six-month difference can be huge. Time flies quickly when you're scrambling to identify alternative suppliers, arrange new stock, advise healthcare professionals and make sure patients aren't left without treatment. Giving the TGA more warning means giving our health system more time to act.

The Albanese Labor government are proud of their long tradition of building, supporting and maintaining the healthcare system in Australia, and this legislation is a continuation of that investment into our health services. That has always been at the heart of Labor's approach to health care. Access is about more than affordability. There is little comfort in having a prescription subsidised through the PBS if the medicine is not available when you need it, and that's why these reforms matter. They are part of the practical work of maintaining and strengthening our healthcare system, ensuring Australians can have confidence that, when they need treatment, the system is better equipped to deliver it. The Albanese Labor government understands that protecting Medicare means looking after the entire healthcare system. It means making medicines more affordable through the PBS, strengthening bulk-billing, investing in the health workforce and ensuring Australians can access care closer to home. It also means making sure our health system has the information and tools it needs to respond to medicines shortages before patients feel the impact. No government can prevent every supply disruption, but we can make sure Australia's health system is better prepared, better informed and focused on protecting patients. Ultimately, these reforms reflect a principle that has guided Labor governments for generations: that Australians deserve a healthcare system that they can trust, and that access to essential treatment should never be taken for granted.

Jenny McAllister

Jenny McAllister NSW, Australian Labor Party, Minister for the National Disability Insurance Scheme

7:37 pm

Many improvements have been made to arrangements to deal with medicines shortages and discontinuance reporting since the introduction of these arrangements in 2019, but supply disruptions do continue to impact the health and wellbeing of people in Australia and the health practitioners and systems that support them. The bill before the chamber, the Therapeutic Goods Amendment (Medicines Shortages and Other Measures) Bill, strengthens key aspects of the mandatory medicines shortage and discontinuation reporting scheme under the Therapeutic Goods Act, principally by requiring sponsors to notify the secretary of any decision to permanently discontinue the supply of reportable medicines in Australia at least 12 months in advance; requiring sponsors who give such notice to update the secretary if there is a change in that approach, including if the supply is no longer proposed to be discontinued or if the discontinuation is to occur at a different time to that notified; and enabling the secretary to require all sponsors of approved medicines to provide information about the availability and any shortage or discontinuation of their products in Australia.

These amendments are consistent with this government's unwavering commitment to public health, and will mitigate the public health risks associated with medicines shortages and discontinuations, by supporting a strong and effective mandatory reporting scheme under the Therapeutic Goods Act. Together with the associated amendments in the Therapeutic Goods (Charges) Amendment Bill 2026, the bill will implement measures to reduce costs and regulatory burden for sponsors who have multiple biologicals in the Australian Register of Therapeutic Goods. These amendments are consistent with this government's commitment to reducing regulatory burden. The other minor amendments in the bill will support the consistent and effective operation of the Therapeutic Goods Act and the therapeutic goods regulatory framework. I thank members for their contribution to the debate on these bills.

Question agreed to.

Bills read a second time.

(Quorum formed)